These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26072731)

  • 1. Arachidonic acid metabolites and endothelial dysfunction of portal hypertension.
    Sacerdoti D; Pesce P; Di Pascoli M; Brocco S; Cecchetto L; Bolognesi M
    Prostaglandins Other Lipid Mediat; 2015 Jul; 120():80-90. PubMed ID: 26072731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.
    Sacerdoti D; Gatta A; McGiff JC
    Prostaglandins Other Lipid Mediat; 2003 Oct; 72(1-2):51-71. PubMed ID: 14626496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology and a Rational Basis of Therapy.
    Gracia-Sancho J; Maeso-Díaz R; Bosch J
    Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension.
    Sacerdoti D; Jiang H; Gaiani S; McGiff JC; Gatta A; Bolognesi M
    Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):72-5. PubMed ID: 21856435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology of portal hypertension.
    Cichoz-Lach H; Celiński K; Słomka M; Kasztelan-Szczerbińska B
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():231-8. PubMed ID: 18812641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.
    Iwakiri Y
    Liver Int; 2012 Feb; 32(2):199-213. PubMed ID: 21745318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
    Sakamoto M; Nakamura T; Torimura T; Iwamoto H; Masuda H; Koga H; Abe M; Hashimoto O; Ueno T; Sata M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):168-78. PubMed ID: 22849788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis.
    Gatta A; Bolognesi M; Merkel C
    Mol Aspects Med; 2008; 29(1-2):119-29. PubMed ID: 18036654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamics in the isolated cirrhotic liver.
    Zipprich A
    J Clin Gastroenterol; 2007; 41 Suppl 3():S254-8. PubMed ID: 17975473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eicosanoids in cirrhosis and portal hypertension.
    Birney Y; Redmond EM; Sitzmann JV; Cahill PA
    Prostaglandins Other Lipid Mediat; 2003 Oct; 72(1-2):3-18. PubMed ID: 14626493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of vasoactive substances and cellular effectors in the pathophysiology of cirrhotic portal hypertension: the past, the present and the future--Georges Brohée Lecture.
    Laleman W
    Acta Gastroenterol Belg; 2009; 72(1):9-16. PubMed ID: 19402365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis.
    Yang YY; Huang YT; Tsai TH; Hou MC; Lee FY; Lee SD; Lin HC
    Clin Sci (Lond); 2012 Dec; 123(12):669-80. PubMed ID: 22734967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic changes in splanchnic blood vessels in portal hypertension.
    Colle I; Geerts AM; Van Steenkiste C; Van Vlierberghe H
    Anat Rec (Hoboken); 2008 Jun; 291(6):699-713. PubMed ID: 18484617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.
    Huang HC; Wang SS; Hsin IF; Chang CC; Lee FY; Lin HC; Chuang CL; Lee JY; Hsieh HG; Lee SD
    Hepatology; 2012 Jul; 56(1):248-58. PubMed ID: 22290687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers.
    Graupera M; García-Pagán JC; Abraldes JG; Peralta C; Bragulat M; Corominola H; Bosch J; Rodés J
    Hepatology; 2003 Jan; 37(1):172-81. PubMed ID: 12500202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress.
    Tai Y; Zhao C; Zhang L; Tang S; Jia X; Tong H; Liu R; Tang C; Gao J
    J Cell Mol Med; 2021 Nov; 25(22):10389-10402. PubMed ID: 34609050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of arachidonic acid by rat adrenal glomerulosa cells: synthesis of hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids.
    Campbell WB; Brady MT; Rosolowsky LJ; Falck JR
    Endocrinology; 1991 Apr; 128(4):2183-94. PubMed ID: 1900788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
    Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
    Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats.
    Hsu SJ; Lee FY; Wang SS; Hsin IF; Lin TY; Huang HC; Chang CC; Chuang CL; Ho HL; Lin HC; Lee SD
    Hepatology; 2015 May; 61(5):1672-84. PubMed ID: 25557829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.